1. Home
  2. Resources
  3. Understanding Axol Products

Understanding Axol Products

Axol-Bioscience-human-iPSC-image-1354171861-1.jpg

Axol: making your models more human

We give you access to more human in vitro models of physiology and disease through cells derived from human induced pluripotent stem cells (iPSCs). Research needs physiologically relevant, robust, and reliable models. We believe human iPSCs deliver exactly that. 

Our focus is on providing you with excitable cells. This means:

  • CiPA-validated cardiomyocytes for in vitro cardiotoxicity screening
  • Central nervous system cells for cell-based models of neurodegenerative diseases
  • Sensory neurons for models of pain and sensory neuron conditions

We research, develop and manufacture at our sites in Roslin and Cambridge UK.

Optimized kits for better results

To make sure you always have the best possible collection of reagents, we’ve built kits. The kits are hand-picked groups of products that include your cells, the cell culture media, and supplemental reagents like our ‘’Maximizer’ products that accelerate cell maturation. All of our kits also include a detailed protocol that shows you how to get the best possible results. 

Take a look at the complete range of kits and individual products. 

Let’s work together

We firmly believe that collaboration between scientists and organizations is what will drive the adoption of more human in vitro research forward. That’s why we’re always available to work closely with you when needed. 

Over the last decade, we’ve developed CiPA-validated cardiomyocytes for preclinical safety screens, and neural stem cells from patients with neurological conditions like Alzheimer’s disease and Parkinson’s disease. We’re also collaborating with NETRI, the organ-on-a-chip manufacturer, to create additional kits made of their devices and our human iPSC, which will open up a host of new research options.

If you’re interested in working more closely with us, get in touch

Axol-Bioscience-human-iPSC-image-A-sit-down-with-Steve-Rees-the-importance-of-understanding-renal-toxicity-in-drug-development.jpeg